| Date |
Title |
Text |
| 05/01/2009 |
Healthcare Reform Summit |
A live video roundtable of the world’s experts on aspects of healthcare reform
Sir Michael Rawlins, Chairman of NICE
Kathy Buto, JNJ VP on government affairs
Bruce Quinn, MD, PhD, MBA, former California Director of Medicare
Mark Schoenebaum, MD, senior biotech analyst at DB
Russell Teagarden, Medco VP of clinical applications of electronic medical records
Bruce Nudell, PhD, senior healthcare analyst at UBS |
| 05/10/2009 |
Conflicts of interest in medicine |
Eric Campbell, PhD, Massachusetts General Hospital, discusses the IOM report on conflicts of interest medicine |
| 05/18/2009 |
Capitol interviews |
Rep Burgess, House leader of the healthcare reform caucus
Mark McClellan, former head of CMS and FDA |
| 05/29/2009 |
ASCO |
|
| 11/03/2009 |
Senator Judd Gregg |
Senator Gregg explains the next steps in Congress for the healthcare reform plans |
| 12/09/2009 |
Interview with Newt Gingrich |
|
| 12/10/2009 |
Interview with Senator Cardin |
|
| 01/20/2010 |
Obesity week |
Interviews with weight loss medical experts about new drugs in development and surgical procedures for weight loss. |
| 05/07/2010 |
MD Anderson Cancer Center President interview |
Dr. Mendelsohn discusses the IOM report on changes recommended at the NCI |
| 06/09/2010 |
Interview with FDA Commissioner |
- |
| 09/22/2010 |
PARTNER data |
cardiology experts to discuss PARTNER data on the Edwards Sapien valve for aortic stenosis |
| 10/29/2010 |
The Weekly Summary show from Miami |
Topics
Bydureon CR delay
Pradaxa approval
CoreValve trials start
St Jude acquisition of AGA
Slow down in elective procedures
Avastin for ovarian cancer |
| 11/15/2010 |
Obesity Summit |
discussion of drugs and devices to treat obesity |
| 11/16/2010 |
Interview with FDA CDER Director Janet Woodcock |
The Director of the FDA's drug center, CDER, Dr. Janet Woodcock discusses a variety of topics in our exclusive video interview |
| 02/16/2011 |
Interview with The Commissioner of the FDA |
|
| 02/28/2011 |
Roundtable with Deans of Johns Hopkins and Miami on ACOs |
|
| 05/13/2011 |
Miami medical center panels |
In conjunction with the research firm ISI and industry analyst Mark Schoenebaum, MD, we will host a series of disease-specific panels to discuss vaccines, Hep C, oncology, diabetes, stem cell, ophthalmology and other topics. Email us if you would like to attend |
| 07/20/2011 |
FDA AdCom for EW Sapien valve |
We will be attending the FDA CDRH advisory committee panel on the new EW percutaneous aortic valve |
| 07/20/2011 |
Interview with Commissioner of the FDA |
Interview with Commissioner of the FDA |
| 09/06/2011 |
Report" Why so many new drugs are not selling well |
Why so many new drugs are not selling well
Over the last three years, the FDA has approved numerous new drugs that solve unmet medical needs, such as lupus, deadly melanoma and hepatitis C, gout, rare forms of lymphoma, safer anticoagulation than warfarin, and others (see our interview with the Director of the FDA's drug division). However, most of these new wonder drugs are not selling well, disappointing shareholders. Why?
Each drug has unique reasons for the poor launches, but a more important macro trend relates to the bad global economy. In non-U.S. countries, governments are pushing back on high drug prices.
To register for a 30-day trial, click here. To subscribe, contact sales@thehcc.tv |
| 01/29/2012 |
Eylea Lucentis Avastin roundtable |
Eylea Lucentis Avastin roundtable
Soon, date to be determined, we will be hosting a discussion with Dr. Rosenfeld of Bascom Palmer to discuss the reasons that Regneron's Eylea is launching so well and taking market share from Roche's Lucentis. As you might know, Dr. Rosenfeld championed more than anyone the self-formulated Avastin as a cheaper alternative to Lucentis. He rarely gives interviews these days. |
